Veterinary Infectious Disease Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Technology (Immunodiagnostics, Molecular Diagnostics, Other Veterinary Diagnostic Technologies), By Animal Type (Companion Animals, Food Producing Animals), By End User (Reference Laboratories, Veterinary Laboratories and Clinics, Point of Care / In House Testing, Research Institutes and Universities), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 1.61 Billion
CAGR (2026-2031)	5.26%
Fastest Growing Segment	Molecular Diagnostics
Largest Market	North America
Market Size (2031)	USD 2.19 Billion

Market Overview

The Global Veterinary Infectious Disease Diagnostics Market will grow from USD 1.61 Billion in 2025 to USD 2.19 Billion by 2031 at a 5.26% CAGR. Veterinary infectious disease diagnostics encompass a range of laboratory instruments, reagents, and immunodiagnostic kits designed to detect viral, bacterial, and parasitic pathogens in livestock and companion animals. The primary drivers supporting market growth include the escalating prevalence of transboundary zoonotic diseases and the critical economic necessity of ensuring global food security through herd health management. Furthermore, the rising trend of pet humanization has resulted in increased willingness among owners to invest in advanced healthcare, thereby stimulating the demand for rapid and accurate pathogen detection. This urgency is highlighted by recent surveillance data which underscores the burden of disease. According to the World Organisation for Animal Health, between January 2024 and May 2025, global monitoring systems reported 14,918 outbreaks of African swine fever and 6,346 outbreaks of high pathogenicity avian influenza.

Despite these strong growth catalysts, the market faces a significant challenge regarding the high acquisition and operational costs associated with advanced molecular diagnostic technologies. These financial constraints often limit the adoption of precise testing methods in developing regions where veterinary budgets are restricted and agricultural sectors are price sensitive. This economic barrier hampers the widespread implementation of state of the art diagnostics in areas where many infectious outbreaks originate, creating a substantial obstacle to the uniform expansion of the global market.

Key Market Drivers

The increasing prevalence of zoonotic and transboundary animal diseases acts as a primary catalyst for market expansion, compelling governments and agricultural bodies to prioritize rigorous surveillance systems to safeguard food security. This heightened focus on biosecurity drives the procurement of advanced diagnostic instruments and reagents capable of rapid pathogen identification in livestock. To address these vulnerabilities, significant financial resources are being directed toward strengthening detection infrastructure. For instance, according to the U.S. Department of Agriculture, May 2024, in the 'USDA Awards $22.2 Million in Farm Bill Funding' announcement, the agency allocated over $22.2 million to 81 projects specifically designed to enhance early detection and rapid response capabilities for threatening animal diseases. Such investments directly subsidize the adoption of diagnostic technologies in the agricultural sector to mitigate economic losses.

Concurrently, the rising adoption of companion animals and the phenomenon of pet humanization are fundamentally reshaping the veterinary services landscape, leading to a surge in expenditure on preventative and diagnostic healthcare. As owners increasingly view pets as family members, their willingness to pay for sophisticated medical testing has grown, incentivizing clinics to upgrade their on-site testing capabilities. According to the American Pet Products Association, August 2024, in the '2024 Dog and Cat Report', total U.S. spending on veterinary care and product sales reached $39.8 billion in 2024. This robust commercial demand is further evidenced by leading industry players; according to IDEXX Laboratories, in 2025, the company reported full-year 2024 revenues of $3.898 billion, underscoring the lucrative nature of the diagnostics sector driven by these dual market forces.

Download Free Sample Report

Key Market Challenges

The primary impediment to market expansion is the prohibitive cost associated with acquiring and operating advanced molecular diagnostic technologies. These sophisticated testing platforms require substantial capital investment and rely on expensive reagents, creating a steep barrier to entry for veterinary clinics and livestock producers with limited budgets. In price-sensitive agricultural sectors and developing regions, these financial demands often force practitioners to rely on traditional, less accurate methods rather than adopting modern diagnostic solutions, thereby stifling the market's potential reach in areas where infectious risks are often highest.

This economic strain is intensified by the broader escalating costs of animal healthcare, which limits the disposable income available for premium diagnostic services. According to the American Animal Hospital Association, in 2025, the lifetime cost of care for a dog increased by 11.65% compared to 2022 levels. Such rising expenses compel pet owners and farmers to scrutinize spending, often resulting in the rejection of high-cost diagnostic procedures in favor of basic symptomatic treatments. Consequently, this financial reticence directly hampers the revenue growth and widespread adoption of advanced diagnostic tools globally.

Key Market Trends

Integration of Artificial Intelligence and Machine Learning in Diagnostics is fundamentally reshaping veterinary practice by automating complex analytical tasks and enhancing diagnostic accuracy. This trend addresses the shortage of specialists by embedding deep learning algorithms into analyzers, enabling practitioners to obtain reference-quality interpretations for cytology and hematology in real-time. This technological leap is evidenced by recent advancements; according to Zoetis Inc., December 2024, in the 'Zoetis to Expand Vetscan Imagyst Capabilities for Improved Veterinary Care' press release, the company announced AI-driven updates to its platform, including a new algorithm capable of identifying and differentiating white blood cells within minutes, thereby streamlining the diagnostic workflow.

Adoption of Point-of-Care and Rapid Diagnostic Testing is shifting infectious disease management from central laboratories to the clinic, allowing for immediate pathogen detection. By utilizing on-site analyzers, veterinarians can rapidly implement biosecurity measures and treatment plans, a capability essential for controlling contagious outbreaks. The market's pivot toward these solutions is quantified by financial performance; according to IDEXX Laboratories, Inc., October 2024, in the 'IDEXX Laboratories Announces Third Quarter Results' report, the company recorded a 10% year-over-year growth in its global premium instrument installed base, underscoring the increasing investment by practices in rapid, in-house diagnostic infrastructure.

Segmental Insights

The molecular diagnostics segment is currently the fastest-growing category within the global veterinary infectious disease diagnostics market. This accelerated expansion is primarily driven by the increasing demand for high-specificity testing methods, such as polymerase chain reaction technology, which enable early and accurate pathogen detection. Furthermore, the rising prevalence of zoonotic diseases has prompted entities like the World Organisation for Animal Health to advocate for stricter surveillance measures, thereby boosting market adoption. The shift towards rapid testing in veterinary clinics further supports this segment by facilitating immediate and effective disease management.

Regional Insights

North America commands the leading position in the Global Veterinary Infectious Disease Diagnostics Market, primarily driven by established animal healthcare infrastructure and substantial veterinary spending. The region benefits from high pet ownership levels and the frequent utilization of diagnostic screening in clinical practice. Furthermore, the concentration of major diagnostic manufacturers within the region accelerates the availability and adoption of molecular and immunodiagnostic technologies. This market stability is underpinned by a robust regulatory framework, exemplified by the USDA Center for Veterinary Biologics, which enforces rigorous standards for the approval and quality control of infectious disease diagnostic kits.

Recent Developments

• In December 2024, Zoetis Inc. announced significant enhancements to its digital microscopy platform, Vetscan Imagyst, to improve its artificial intelligence-driven diagnostic capabilities. The company introduced an update to its fecal analysis application, enabling the system to automatically recognize and identify Spirometra species tapeworms, a parasitic agent of concern in veterinary medicine. Additionally, the update included advancements in urine sediment analysis to identify specific crystals indicative of pathology. These innovations were developed to provide veterinarians with more precise and rapid diagnostic results, facilitating timely treatment decisions for infectious and internal medicine conditions in companion animals.
• In July 2024, Mars, Incorporated completed the acquisition of an ownership stake in two French veterinary diagnostic businesses, Cerba Vet and ANTAGENE, from Cerba HealthCare. This strategic move integrated the acquired entities into the Science & Diagnostics division of the company, thereby broadening its diagnostic footprint in the European market. The collaboration was intended to enhance access to advanced diagnostic solutions, including infectious disease testing and genetics, for veterinary professionals and pet owners in France. This expansion reinforced the company's commitment to delivering comprehensive health solutions and leveraging global expertise to improve veterinary care standards.
• In March 2024, IDEXX Laboratories, Inc. expanded its reference laboratory testing portfolio by launching a new fecal antigen test for the detection of Cystoisospora. This intestinal parasite, which frequently affects young dogs and cats, can now be identified with greater accuracy through the company's proprietary antigen testing platform. The introduction of this test in North America marked a significant advancement in the early detection and treatment of parasitic infections. This product launch was part of the company's broader strategy to enhance its diagnostic offerings and support veterinary professionals in addressing common infectious diseases more effectively.
• In January 2024, Center Point Bio-Tech, LLC launched a novel veterinary diagnostic system known as AlphaION during a major industry exhibition. This innovative platform was designed to automate bacterial culture and sensitivity testing directly within veterinary clinics, a process that was traditionally relegated to outside reference laboratories. The system utilizes advanced automation to streamline clinical workflows and improve the management of complex infectious disease cases. By providing rapid and accurate diagnostic capabilities at the point of care, this development aims to significantly enhance patient outcomes and expand access to critical testing for companion and production animals.

Key Market Players

• BIOMÉRIEUX
• Heska Corporation
• Neogen Corporation
• INDICAL BIOSCIENCE GmbH
• Randox Laboratories Ltd.
• Thermo Fisher Scientific Inc.
• Creative Diagnostics
• DRG INSTRUMENTS GMBH
• Chembio Diagnostic Systems, Inc.
• Eurofins Technologies
• Agrolabo S.p.A.
• Abbott Laboratories inc.
• Danaher Corporation

By Technology	By Animal Type	By End User	By Region
Immunodiagnostics Molecular Diagnostics Other Veterinary Diagnostic Technologies	Companion Animals Food Producing Animals	Reference Laboratories Veterinary Laboratories and Clinics Point of Care / In House Testing Research Institutes and Universities	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Veterinary Infectious Disease Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Veterinary Infectious Disease Diagnostics Market, By Technology:

• Immunodiagnostics
• Molecular Diagnostics
• Other Veterinary Diagnostic Technologies

• Veterinary Infectious Disease Diagnostics Market, By Animal Type:

• Companion Animals
• Food Producing Animals

• Veterinary Infectious Disease Diagnostics Market, By End User:

• Reference Laboratories
• Veterinary Laboratories and Clinics
• Point of Care / In House Testing
• Research Institutes and Universities

• Veterinary Infectious Disease Diagnostics Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE